Earnings Feed
Start Free
Home/Filings/4/0001209191-14-013781
4//SEC Filing

NUPATHE INC. 4

Accession 0001209191-14-013781

CIK 0001375200operating
View on SEC.govCompany Profile

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 12:12 PM ET

Size

45.4 KB

Accession

0001209191-14-013781

Insider Transaction Report

Form 4
Period: 2014-02-21
NUPATHE INC.PATH
ROCHE ROBERT P JR
Director
Transactions
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21−7,486→ 0 total
    Exercise: $10.00Exp: 2020-08-05→ Common Stock (7,486 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21−2,024→ 0 total
    Exercise: $7.81Exp: 2021-03-31→ Common Stock (2,024 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$4.78/sh−9,050$43,259→ 0 total
    Exercise: $2.02Exp: 2021-09-30→ Common Stock (9,050 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$4.96/sh−9,955$49,377→ 0 total
    Exercise: $1.84Exp: 2021-12-30→ Common Stock (9,955 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.43/sh−6,750$23,153→ 0 total
    Exercise: $3.37Exp: 2022-06-07→ Common Stock (6,750 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.35/sh−4,099$13,732→ 0 total
    Exercise: $3.45Exp: 2023-03-31→ Common Stock (4,099 underlying)
  • Disposition from Tender

    Common Stock

    2014-02-21$6.80/sh−10,000$68,000→ 0 total
  • Disposition to Issuer

    Common Stock

    2014-02-21$6.80/sh−13,500$91,800→ 0 total
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21−6,014→ 0 total
    Exercise: $7.75Exp: 2021-03-03→ Common Stock (6,014 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21−6,750→ 0 total
    Exercise: $7.66Exp: 2021-06-08→ Common Stock (6,750 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.10/sh−4,976$15,426→ 0 total
    Exercise: $3.70Exp: 2022-03-31→ Common Stock (4,976 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$2.77/sh−4,326$11,983→ 0 total
    Exercise: $4.03Exp: 2022-06-30→ Common Stock (4,326 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.74/sh−5,787$21,643→ 0 total
    Exercise: $3.06Exp: 2023-06-30→ Common Stock (5,787 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$4.39/sh−8,951$39,295→ 0 total
    Exercise: $2.41Exp: 2023-09-30→ Common Stock (8,951 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.53/sh−6,604$23,312→ 0 total
    Exercise: $3.27Exp: 2023-12-31→ Common Stock (6,604 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21−2,169→ 0 total
    Exercise: $7.33Exp: 2021-06-30→ Common Stock (2,169 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.24/sh−4,956$16,057→ 0 total
    Exercise: $3.56Exp: 2022-09-30→ Common Stock (4,956 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.42/sh−5,179$17,712→ 0 total
    Exercise: $3.38Exp: 2022-12-31→ Common Stock (5,179 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.81/sh−13,500$51,435→ 0 total
    Exercise: $2.99Exp: 2023-06-05→ Common Stock (13,500 underlying)
Footnotes (4)
  • [F1]Disposed upon the consummation of the merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated January 17, 2014, among the issuer, Teva Pharmaceutical Industries Ltd. and Train Merger Sub, Inc.(the "Merger Agreement"), in exchange for $3.65 per share, plus contractual rights to receive up to an additional $3.15 in contingent cash consideration payments per share.
  • [F2]Includes all restricted stock units that became fully vested upon the consummation of the Merger.
  • [F3]Pursuant to the Merger Agreement, all options became fully vested upon the consummation of the Merger.
  • [F4]Pursuant to the Merger Agremeent, the option was converted into the right to receive, at the earliest date at which the sum of (1) the $3.65 per share cash portion of the merger consideration and (2) the amount per share in cash previously paid or to be paid at such date in connection with the Contingent Cash Consideration Agreement entered into in connection with the Merger Agreement (such sum, the "Per Share Paid Value") exceeds the per-share exercise price under the option: (x) an amount in cash equal to the number of shares of common stock subject to the option multiplied by the excess of (i) the then applicable Per Share Paid Value over (ii) the per-share exercise price under the option; and (y) the right to receive, in respect of each share of common stock subject to the option, each contingent cash consideration payment that, as of such date, has not yet become payable.

Documents

1 file

Issuer

NUPATHE INC.

CIK 0001375200

→
Entity typeoperating

Related Parties

1
  • filerCIK 0001375200

Filing Metadata

Form type
4
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 12:12 PM ET
Size
45.4 KB
View on SEC.gov